Tocqueville Asset Management L.P. decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 1.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 20,144 shares of the medical instruments supplier’s stock after selling 266 shares during the period. Tocqueville Asset Management L.P.’s holdings in Becton, Dickinson and were worth $3,947,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BDX. Mawer Investment Management Ltd. raised its holdings in Becton, Dickinson and by 1.3% in the first quarter. Mawer Investment Management Ltd. now owns 1,768,539 shares of the medical instruments supplier’s stock valued at $324,418,000 after buying an additional 22,563 shares during the period. JPMorgan Chase & Co. raised its holdings in Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after buying an additional 242,081 shares during the period. YHB Investment Advisors Inc. raised its holdings in Becton, Dickinson and by 95.6% in the first quarter. YHB Investment Advisors Inc. now owns 20,289 shares of the medical instruments supplier’s stock valued at $3,793,000 after buying an additional 9,915 shares during the period. KBC Group NV raised its stake in shares of Becton, Dickinson and by 7.0% during the first quarter. KBC Group NV now owns 42,988 shares of the medical instruments supplier’s stock valued at $7,886,000 after purchasing an additional 2,816 shares during the period. Finally, Prudential Financial Inc. raised its stake in shares of Becton, Dickinson and by 34.0% during the first quarter. Prudential Financial Inc. now owns 930,445 shares of the medical instruments supplier’s stock valued at $170,681,000 after purchasing an additional 236,280 shares during the period. Hedge funds and other institutional investors own 86.71% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/11/08/tocqueville-asset-management-l-p-cuts-position-in-becton-dickinson-and-company-bdx.html.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at $221.27 on Wednesday. Becton, Dickinson and Company has a 1 year low of $161.29 and a 1 year high of $225.23. The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56. The firm has a market cap of $50,564.94, a P/E ratio of 23.41, a PEG ratio of 1.74 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. During the same quarter last year, the company earned $2.12 earnings per share. The business’s quarterly revenue was down 2.0% compared to the same quarter last year. research analysts expect that Becton, Dickinson and Company will post 10.6 EPS for the current fiscal year.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction on Friday, September 8th. The stock was sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the completion of the transaction, the insider now directly owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Insiders have sold 69,933 shares of company stock valued at $14,063,953 in the last three months. Corporate insiders own 1.40% of the company’s stock.

A number of analysts have recently issued reports on the stock. Barclays PLC reiterated an “equal weight” rating and set a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective on the stock in a research note on Tuesday, October 31st. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Five research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $213.47.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.